Blog

  • Pakistan withdraws from Asia Cup Hockey 2025, citing security concerns: HOI President Dilip Kumar Tirkey

    Pakistan withdraws from Asia Cup Hockey 2025, citing security concerns: HOI President Dilip Kumar Tirkey

    New Delhi [India], August 19 (ANI): Hockey India president Dilip Kumar Tirkey on Tuesday stated that Pakistan’s withdrawal from the Asia Cup Hockey in Bihar later this month is because they are refusing to come all by themselves due to security reasons.

    The upcoming Asia Cup Hockey in Rajgir, Bihar, has seen some changes, with Pakistan and Oman withdrawing from the tournament. The event, scheduled from August 29 to September 7, will now welcome Bangladesh and Kazakhstan as replacements.

    “Asia Cup is a very important tournament in Asian hockey. Pakistan is not coming to this tournament due to security reasons. India never refused them; they are refusing to come all by themselves due to security reasons…Oman team has also withdrawn due to their personal issues with their Government,” Dilip Kumar Tirkey told ANI.

    “Pakistan is not playing in the Asia Cup. Pakistan Hockey Federation itself refused to come due to security reasons. We do not have anything to say,” he further added.

    Pakistan, traditionally one of the biggest names in Asian hockey, will not participate, paving the way for Bangladesh to make the cut. Oman too decided against participation, with Kazakhstan taking their place in the competition.

    The Asian Hockey Federation (AHF) announced the official match schedule for the Asia Cup Rajgir, Bihar 2025 on Tuesday. This prestigious continental championship will not only crown the best team in Asia, but also the winners of Asia Cup 2025 will qualify for the FIH Hockey World Cup, Belgium, Netherlands 2026.

    The tournament will open on August 29 with an exciting day of action, featuring reigning champions Korea beginning their title defence against Chinese Taipei, and hosts India facing China in front of an expected passionate home crowd.

    After facing China, the hosts will face Japan on August 31, and will play their final group game on September 1 against Kazakhstan.The participating nations are divided into two pools: Pool A consists of India, Japan, China, and Kazakhstan, while Pool B includes Malaysia, Korea, Bangladesh, and Chinese Taipei.

    The pool stage will be followed by the Super4s, with the Final on September 7 between the teams finishing first and second in the Super4s. The champion will lift the Asia Cup 2025 Trophy and secure Asia’s spot at the FIH Hockey World Cup Belgium-Netherlands 2026. (ANI)

    (This content is sourced from a syndicated feed and is published as received. The Tribune assumes no responsibility or liability for its accuracy, completeness, or content.)


    Continue Reading

  • Real Madrid vs Osasuna Predictions and Betting Tips: Week 1 win for Los Blancos

    Real Madrid vs Osasuna Predictions and Betting Tips: Week 1 win for Los Blancos

    Real Madrid have won their last 20 competitive meetings with Osasuna, making them ideal opponents for Los Blancos to start the new La Liga campaign.

    Best bets for Real Madrid vs Osasuna

    • Real Madrid to score in Both Halves @ -126 with bet365
    • Real Madrid -2 (Handicap 3-Way) @ +162 with bet365 
    • Gonzalo Garcia Anytime goalscorer @ +120 with bet365 

    All odds are courtesy of bet365, correct at the time of publishing and subject to change.

    Los Blancos to net in both halves

    Real Madrid have scored first in their last eight competitive meetings with Osasuna. They’ve also led at halftime in their last five clashes. This suggests that Los Blancos will score first in the opening 45 minutes.

    Then they will add to their lead in the second period. They have plenty of firepower to extend their lead even without Jude Bellingham and Endrick.

    Goals are almost certain as Real and Alonso will be keen to show Barcelona that they’re strong title contenders.

    • Real Madrid vs Osasuna Bet 1: Real Madrid to score in Both Halves @ -126 with bet365

    Backing a three-goal winning margin for Real

    Los Blancos have won 4-0 in their last two home matches at the Bernabeu against Osasuna.

    That’s why it’s surprising that the betting markets indicate that there’s only a 37% probability of Real winning by three or more goals on Tuesday evening.

    Real’s odds to win the match outright are far too short to consider. Therefore, backing them to win by a three-goal margin or better is the value pick of these Real Madrid vs Osasuna predictions.

    • Real Madrid vs Osasuna Bet 2: Real Madrid -2 (Handicap 3-Way) @ +162 with bet365

    Garcia to start strongly off the bench

    Gonzalo Garcia, a young player from Real Madrid’s academy, had a remarkable rise to fame this summer at the Club World Cup.

    The 21-year-old was named the top scorer of the entire competition, having scored four goals and one assist in six games. Although Alonso is unlikely to start Garcia against Osasuna, he’s primed and ready to go from the bench.

    That’s why he is worth backing to score as a second-half substitute against a tired Osasuna side.

    • Real Madrid vs Osasuna Bet 3: Gonzalo Garcia Anytime goalscorer @ +120 with bet365

    Our analysis: Form of both teams

    Real Madrid will host Osasuna to kick off the new 2025/26 La Liga season. Xabi Alonso’s men are eager to start strongly against a team they’ve not lost to since 2011.

    Los Blancos will then start the new campaign without some players, with Jude Bellingham and Endrick sidelined. Additionally, central defender Antonio Rudiger finishes his six-game ban from last season.

    This is not an ideal situation, with Alonso still unsure of his best starting XI. However, there’s still plenty of firepower to hurt Osasuna. Locally developed forward Gonzalo Garcia will once again be keen to make an impact off the bench.

    Osasuna could well be without the services of Iker Benito and Ruben Garcia, as they require late fitness tests. New recruit Rosier is likely to make his first La Liga start for the visitors at full back.

    The visitors’ main attacking threat, Ante Budimir, will be the key player for Real to be wary of on Tuesday evening. Budimir scored 21 goals last season, which placed him among the top goalscorers such as Kylian Mbappe and Robert Lewandowski.

    Probable lineups for Real Madrid vs Osasuna

    Real Madrid expected lineup: Courtois; Alexander-Arnold, Militao, Huijsen, Carreras, Tchouameni, Valverde, Guler, Brahim, Vinicius, Mbappe

    Osasuna expected lineup: Herrera; Catena, Rosier, Bretones, Boyomo, Torro, Oroz, Moncayola, Barja, Gomez, Budimir

    Continue Reading

  • Colin Farrell Stars in Netflix Film

    Colin Farrell Stars in Netflix Film

    Netflix has unveiled the first trailer for Edward Berger‘s “Ballad of a Small Player,” starring Colin Farrell.

    In the film, Farrell plays Lord Doyle, a man who spends all day and night on the casino floors of Macau. As he struggles to keep up with his debts, Fala Chen’s Dao Ming, a casino employee, surfaces to save him. Meanwhile, Tilda Swinton plays a private investigator named Cynthia Blithe who is hot on his trail and ready to confront him about his past.

    The psychological thriller is Berger’s follow-up to “Conclave” and is based on a book by Lawrence Osborne. The screenplay is adapted by Rowan Joffe, best known for writing “28 Weeks Later” (2007). 

    The film reunites Berger with his team of artisans, including cinematographer James Friend, production designer Jonathan Houlding, costume designer Lisy Christl, editor Nick Emerson and composer Volker Bertelmann.

    Berger has earned acclaim in recent years. His German-language remake of “All Quiet on the Western Front” (2022) was nominated for best picture and won four Academy Awards, including international feature. It also set a BAFTA record with seven awards, the most ever in the history of the awards. Berger followed that success with “Conclave,” which secured a best adapted screenplay Oscar for Peter Straughan earlier this year.

    Farrell is enjoying a banner year after earning his first Emmy nomination for portraying the menacing Oz Cobb in the Batman spinoff miniseries “The Penguin.”

    Netflix has slated the film for a prime release: it opens in U.S. theaters on Oct. 15, arrives in U.K. and Ireland cinemas on Oct. 17, and debuts on the streamer on Oct. 29. Before that, the film will screen at TIFF and other fall film festivals, including the Zurich Film Festival where Farrell will receive the Golden Icon Award. 

    “Ballad of a Small Player” is produced by Mike Goodridge and Matthew James Wilkinson.

    Watch the trailer below.

    Continue Reading

  • Colin Farrell Stars in Netflix Movie

    Colin Farrell Stars in Netflix Movie

    Colin Farrell finds himself in a high-stakes state of mind in the teaser trailer for Netflix‘s Ballad of a Small Player.

    Netflix releases Edward Berger‘s feature in select U.S. theaters Oct. 15 and in select U.K. and Ireland theaters two days later before it begins streaming Oct. 29. Fala Chen, Deanie Ip, Alex Jennings and Tilda Swinton round out the cast.

    Ballad of a Small Player centers on Lord Doyle (Farrell), a high-stakes gambler who is dealing with debts and his questionable past. While trying to keep a low profile in Macau, he receives a tempting offer from mysterious casino employee Dao Ming (Chen) while also avoiding private investigator Cynthia Blithe (Swinton).

    The eye-catching trailer features a collection of quick scenes as Farrell is shown sitting on the floor of the shower, cracking open a lobster in a hotel room, screaming during a card game and watching a raging fire.

    “I may be out of puff, but I still have my balls,” Farrell declares in the footage.

    Berger helmed the film from a script by Rowan Joffe that is based on author Lawrence Osborne’s 2014 novel. Berger, Mike Goodridge and Matthew James Wilkinson serve as producers.

    Colin Farrell (left) and Fala Chen in Ballad of a Small Player.

    Courtesy of Netflix

    Ballad of a Small Player is set to premiere next month at the Toronto International Film Festival before screening at other fall festivals. Farrell is set to receive the Golden Icon Award when the movie plays at the Zurich Film Festival on Sept. 27.

    Berger directed Netflix’s 2022 film All Quiet on the Western Front, which was nominated for nine Oscars. His most recent film was last year’s thriller Conclave, with the Focus Features release landing the Academy Award for best adapted screenplay.

    Continue Reading

  • Positive association between the ratio of neutrophil to high-density l

    Positive association between the ratio of neutrophil to high-density l

    Introduction

    Diabetes mellitus (DM) has emerged as a global health issue, affecting 589 million adults worldwide in 2024, with projections indicating a staggering rise to 853 million by 2050.1 Of note, the incidence of diabetes mellitus (DM) has soared dramatically in China over the past few decades, establishing the country as a key epicenter of this epidemic.2 Insulin resistance and insufficient insulin secretion are two underlying mechanisms that lead to diabetes development. However, there is no ideal biomarker that can capture this disorder. The role of inflammation in the development of insulin resistance and pancreatic beta-cell dysfunction has been fully confirmed.3,4 It not only creates an inflammatory microenvironment within the pancreas, impairing the insulin secretion capability of beta cells,5 but also induces insulin resistance in insulin-target tissues like the liver, white adipose tissue, and skeletal muscle.6

    Figure 1 The flow chart of study participants selection.

    Abbreviations: FPG, fasting plasma glucose; HbA1C, glycated hemoglobin A1C.

    As pro-inflammatory cells, neutrophils have been confirmed to contribute critically to the pathogenesis in many chronic inflammatory conditions, including atherosclerosis, diabetes, non-alcoholic fatty liver disease, and autoimmune disorders.7 Additionally, researches indicate that neutrophils are associated with insulin resistance, pancreatic beta-cell dysfunction, and consequently with the development of type 2 diabetes.8 Conversely, high-density lipoprotein cholesterol (HDL-c) is considered to be a protective factor with potent anti-inflammatory effect,9 and it has been recognized as a potential antidiabetic factor by stimulating insulin secretion and cellular glucose uptake.10–13 As a composite biomarker of inflammation, the neutrophil-to-HDL-C ratio (NHR) has been demonstrated to be associated with the incidence of metabolic syndrome14 and various cardiovascular diseases.15,16 However, there remains a scarcity of studies exploring the relationship between NHR and diabetes risk. Therefore, this longitudinal study aimed to examine the relationship between the NHR and new-onset diabetes in a cohort of individuals with normal blood glucose levels. Our findings indicate that elevated NHR was positively associated with an increased risk of diabetes, which may be used as a further valuable marker for early diabetes prediction.

    Methods

    Study Population

    The participants in this study were recruited from individuals who underwent health checkup at the Third Xiangya Hospital of Central South University between January 2017 and March 2024. The current analysis encompassed all study participants who (1) were aged ≥18 years at baseline, (2) completed the first examination between 2017 and 2018, and (3) had made at least three visits between 2017 and 2024 (n=16658). The flowchart of the exclusion criteria in this study is shown in Figure 1. Of the 16658 participants, 3789 participants were excluded according to the exclusion criteria, which were (1) fasting plasma glucose (FPG) ≥6.1mmol/l or glycated hemoglobin A1C (HbA1C) ≥6.5% or with a history of diabetes or pre-diabetes (n=1866), (2) with severe acute and chronic inflammation (n=43), (3) consumption of lipid-lowering drugs (ezetimibe, statins, fibrinogen, and omega-3 fatty acids and cholesterol blockers), antihypertensive drugs or hormone therapies (n=731), (4) with malignant tumors (n=105), (5) with a history of severe cardiovascular, hepatic or renal, diseases (n=52), (6) lack of complete clinical or follow-up data (n=992).

    All participants provided their informed consent for the anonymous use of their medical data and biological samples for scientific research purposes. The Ethical Committee of the Third Xiangya Hospital of Central South University approved the present study (Ethics Board Approval Number: F241043), which adhered to the principles outlined in the Declaration of Helsinki (1975).

    The Definitions of Diabetes and Study Date

    According to the American Diabetes Association’s diagnosis of Diabetes,17 diabetes was diagnosed if participants met ≥1 criterion in the follow-up examinations: 1) diabetes was defined as a fasting blood glucose level ≥126 mg/dL (≥7.0 mmol/L), 2) HbA1c level ≥6.5%; 3) a documented diagnosis of diabetes (ICD-10 code E11–14), or 4) a prescription for any anti-diabetic medication, including insulin, sulfonylureas, metformin, α-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose cotransporter-2 inhibitors, or others.

    The baseline of the study was defined as the day of the first health checkup (2017–2018). For the participants who developed diabetes during the follow-up period, the endpoint was the date of initial diagnosis. For non-diabetic cases, the endpoint was the last recorded health checkup.

    Data Collection and Definition

    Standardized questionnaires were used to record medical history and lifestyle factors including smoking status, alcohol consumption, work intensity, emotional state, and habit of exercise for every examination. Exercise habits were defined as engaging in any physical activity ≥1 time/week. The definition of smoking is continuous smoking for more than 6 months at least 1 cigarette per day. The definition of alcohol consumption is an average of ≥1 time per week, with continuous drinking for more than 6 months. Additionally, anthropometric and hemodynamic parameters (body mass index [BMI], systolic blood pressure [SBP], diastolic blood pressure [DBP]) were assessed during the physical examination. Analysis of fasting blood samples collected at baseline: 1) Hematological indicators (white blood cells [WBC], hemoglobin, platelets, neutrophils, lymphocytes, monocytes); 2) Liver enzyme indicators (ALT); 3) Lipid parameters (HDL-c, total cholesterol [TC], triglycerides [TG]); 4) Renal Function Indicators: (Serum uric acid [SUA] and Creatinine [Cr]. NHR values were calculated by dividing the neutrophil counts to HDL-c level. FPG and HbA1c were tested for every examination. Finally, incident diabetes was defined as meeting ≥1 criterion: HbA1c≥6.5%, FPG≥7.0 mmol/L, or self-reported by standardized questionnaires.

    Statistical Analysis

    The participants were divided into quartile groups (Q1, Q2, Q3, and Q4) according to their NHR values, and the baseline characteristics were compared among the groups. Categorical variables were presented as n (%). Continuous data were summarized as mean ± standard deviation (SD) or median and interquartile ranges [M (IQR)] for normally and non-normally distributed variables, respectively. The comparison of continuous variables across different groups utilized ANOVA with a post hoc Tukey honest significant difference test for normally distributed data, the Kruskal–Wallis test or the Wilcoxon rank-sum test for continuous data with non-normal distribution and Chi-square tests for categorical variables. To evaluate the association between the NHR and the incidence of diabetes, we estimated and compared diabetes incidence by the Kaplan–Meier method and the Log rank test. Multivariate Cox proportional hazards regression models were to assess NHR as an independent predictor of diabetes, after adjusting for confounders including age, gender, BMI, systolic blood pressure, total cholesterol, triglycerides, LDL-c, smoking status, alcohol consumption, exercise participation, job type, number of working days per week, sedentary time outside of work hours, sleep quality, adverse emotions, and family history of diabetes. The area under the receiver operating characteristic (ROC) curves quantified the predictive capacity of NHR for diabetes incidence. We further assessed the incremental predictive value from adding the NHR to FPG to predict diabetes risk. Subgroup analyses were conducted by a stratified Cox proportional hazards regression model. We adjusted for all factors within each stratification, including age, gender, BMI, SBP, TC, TG, LDL-c, smoking status, alcohol consumption, exercise participation, job type, number of working days per week, sedentary time outside of work hours, sleep quality, adverse emotions, and family history of diabetes, but not adjusted for stratification variables in each model. All tests were two-sided, and a p-value <0.05 was considered statistically significant. The missing data for the variables in the analyses were imputed using mean/median/mode imputation.

    All statistical analyses were conducted using SPSS version 29.0 software (IBM Corporation, Chicago, IL, USA).

    Results

    Baseline Characteristics

    The baseline characteristics of the participants grouped according to quartiles of the NHR are detailed in Table 1. The mean age of the subjects was 39.62±11.33 (18–90) years, and 5,717 (44.42%) participants were male. Participants in the top quartile of NHR were more likely the male and had a higher percentage of smokers and drinkers, a higher proportion engaged in mental work or working more than 5 days a week or sedentary time outside work exceeding 4 hours and had higher BMI, WBC, hemoglobin, platelet count, neutrophil count, monocyte count, lymphocyte count, SBP, FPG, TG, SUA, Cr, ALT (P < 0.05). Participants in the bottom quartile of NHR were more likely to have a lower percentage of smokers and drinkers, a higher proportion engaged in working less than 5 days a week or participation in physical activity or sedentary time outside work less than 2 hours and have lower BMI, WBC count, hemoglobin, platelet count, neutrophil count, monocyte count, lymphocyte count, SBP, FPG, TG, SUA, Cr, and ALT (P < 0.05).

    Table 1 Baseline Characteristics of the Study Participants According to the NHR

    The Predictive Value of NHR for Diabetes Incidence

    The participants were followed up for an average duration of 5.11 ± 0.95 years (ranging from 3 to 7 years), and the average diabetes incidence rate was 3.16%. To investigate the impact of varying NHR levels on the cumulative probability of developing diabetes mellitus (DM), a Kaplan–Meier analysis was conducted. As depicted in Figure 2, the cumulative incidence of diabetes in the upper quartile of NHR was notably higher than that in the lower quartile. Statistical significance between these groups was confirmed by the Log rank test (χ2 = 77.923, P < 0.01). Consistently, the Q4 group exhibited the highest diabetes incidence rate of 5.59%, which was 6.5 times higher compared to the Q1 group.

    Figure 2 The estimated cumulative incidence of diabetes mellitus according to the NHR. Kaplan–Meier curves for the cumulative diabetes probability according to different NHR. Q1<1.91; Q2: 1.91–2.52; Q3: 2.52–3.34; Q4>3.34. NHR, neutrophil to high density lipoprotein cholesterol ratio; Cumulative incidence is 1-survival rate. p-value is from the Log rank test.

    To further examine the association of NHR with diabetes incidence, we developed three Cox proportional hazards regression models as shown in Table 2. In Model 1 and Model 2, the NHR was a significant factor for diabetes development. After adjustment for additional confounders in Model 3, this association remained significant for NHR analyzed as both a categorical and continuous variable. The test for trends across quartiles of the NHR for the risk of diabetes was statistically significant (P for trend < 0.001) in both the whole population and male/female subgroups (Tables S1S2). Furthermore, neutrophils and HDL-C, when considered as individual biomarkers, were also significant independent factors for diabetes development (Table S3). In addition, when we set the lowest quartile as a reference, the highest quartile of NHR was distinctly associated with increased risk of diabetes (Crude model, Q4: HR=5.45, 95% CI: 3.45–8.60, P < 0.001) (Model 1, Q4: HR=4.50, 95% CI: 2.81–7.22, P < 0.001), (Model 2, Q4: HR=2.71, 95% CI: 1.64–4.48, P < 0.001) (Model 3, Q4: HR=2.80, 95% CI: 1.64–4.79, P < 0.001).

    Table 2 Cox Proportional Hazards Regression Results for Diabetes Incidence According to the NHR

    To assess the discrimination and reclassification of NHR with and without FPG for the prediction of diabetes. We examined the area under the curves (AUCs) of FPG, NHR, and the combination of NHR and FPG. As illustrated in Figure 3, FPG demonstrates superior predictive capability compared to the NHR. The AUCs obtained from the receiver operating characteristic (ROC) analyses were 0.735 (95% CI: 0.702–0.771, p < 0.001) for FPG, 0.669 (95% CI: 0.63–0.70, p < 0.001) for NHR, and 0.768 (95% CI: 0.739–0.802, p < 0.001) for the combination of NHR and FPG, respectively. Based on the highest Youden’s index,18,19 the optimal thresholds were 5.51 for FPG and 3.25 for NHR. For the combination of NHR and FPG, the optimal FPG and NHR thresholds were 5.55 and 1.69, respectively. Additionally, we found that the area under the ROC curve of NHR is larger than that of neutrophils (AUC =0.669, 95% CI: 0.63–0.70 vs AUC = 0.591, 95% CI: 0.560–0.632), but smaller than that under the ROC curve of HDL-c (AUC = 0.669, 95% CI: 0.63–0.70 vs AUC = 0.690, 95% CI: 0.662–0.729). To determine if there were significant differences between these ROC curves, we conducted pairwise comparisons using DeLong’s test. In all comparisons, the p-values were less than 0.01.

    Figure 3 ROC curves of NHR, FPG and the combination of FPG and NHR to predict type 2 diabetes mellitus (T2DM). a, the p value of the combination of FPG and NHR compared with FPG. b, the p value of the FPG compared with NHR.

    The Predictive Value of NHR for Diabetes Incidence in Various Subgroups

    To investigate whether the predictive value of the NHR index was remained consistent across participants with varying demographic characteristics, various subgroup analyses were performed (Figure 4). Our findings revealed that the NHR serves as a notable predictor of the development of new diabetes regardless of gender, age, BMI, smoking status, emotional distress, occupation type or weekly working duration. Among those who engaged in physical activity have good sleep quality, without a family history of diabetes or never drink, the predictive ability of the NHR was more prominent. Further subgroup analyses showed no significant interactions between NHR and gender, BMI, smoking status, alcohol consumption, participation in exercise, sleep quality, occupation type or weekly working duration. However, it was observed that age and adverse emotions could modify the relationship between NHR and diabetes incidence (All P for interaction <0.05). Specifically, a stronger association was shown in the subjects with age ≥ 40y (HR =1.25, 95% CI 1.09–1.42) and the individuals sometimes or frequently experience anxiety (HR =1.46, 95% CI 1.20–1.78) or depression (HR=1.39, 95% CI 1.16–1.65). In contrast, weaker association was detected in the subjects with age < 40y (HR=1.24, 95% CI 1.07–1.45), participants rarely experience anxiety (HR=1.16, 95% CI 1.03–1.31) or depression (HR=1.17, 95% CI 1.03–1.32) (Figure 4).

    Figure 4 Subgroup analyses for the association of NHR index with new onset of diabetes. Model 1: Adjusted for age and gender; Model 2: Adjusted for BMI, systolic blood pressure, total cholesterol, triglycerides, and LDL-C on the basis of Model 1; Model 3: Adjusted for smoking, alcohol consumption, physical exercise, job type, working days, sedentary time outside of work, sleep quality, adverse emotions, and family history of diabetes on the basis of Model 2.

    Abbreviations: HR, Hazard Ratio; CI, Confidence Interval.

    Discussions

    This large population-based retrospective cohort provides the first evidence that elevated NHR is an independent predictor of T2DM incidence. Even after adjustment for the association potential confounding risk factors, a distinct and independent correlation between the NHR and diabetes development remained. Considering preventability and the substantial benefits of early intervention of T2DM, this simple and practical indicator offers the potential for early identification or intervention strategies to significantly slow down or even prevent the transition from normoglycemia to diabetes on a large scale.

    T2DM has emerged as a significant global threat. Our study demonstrated that the average incidence rate of diabetes was 3.16%, which is consistent with previous research findings. Yan et al in 2019 reported the 5-year incidence of type 2 diabetes in Chinese adults is 3.8%.20 It is marginally higher than our findings. In contrast to their study, which included individuals with prediabetes, our investigation exclusively enrolled participants with normal blood glucose levels at baseline, thereby focusing on the early identification of diabetes risk factors in a normoglycemic population. Additionally, Man et al in 2017 demonstrated a cumulative incidence rate of Type 2 diabetes mellitus (T2DM) of 3.2% over a six-year follow-up period in a normoglycemic Singaporean Malay cohort, a figure which is close to the incidence rates observed in our study.21 This consistency in results across distinct ethnic cohorts strengthens the generalizability of the findings. Furthermore, it is worth noting that our research spanned from 2017 to 2024, during which the world experienced the global pandemic of the coronavirus disease 2019 (COVID-19). Increased incidence of new-onset diabetes and dyslipidemia has been documented in patients following a COVID-19 diagnosis.22,23 However, our research indicated that the diabetes incidence had not increased compared to the pre-pandemic period. This situation might be due to the increased testing during the diagnosis and treatment of COVID-19,24 which may lead to an increase in the diagnosis of diabetes and hyperlipidemia.

    In the pathogenesis of type 2 diabetes mellitus (T2DM) among the Chinese population, both insulin resistance and decline in insulin secretion function play pivotal roles.2 Methods such as the hyperinsulinemic-euglycemic clamp technique or the oral glucose tolerance test (OGTT) combined with insulin release tests have been proposed to measure insulin resistance or insulin secretion function. However, their applicability is limited due to their complexity or cumbersome calculations. Emerging evidence has established diabetes as a chronic inflammatory condition, with persistent low-grade inflammation contributing significantly to the pathogenesis of insulin resistance and pancreatic β-cell impairment.4 Furthermore, Inflammation affects all-cause and cause-specific mortality in patients with diabetes or prediabetes.25 The NHR, as a novel inflammatory biomarker, has been established as a new biomarker for predicting the peripheral arterial disease26 and the presence, progression, and severity of ACS in T2DM population.27 What’s more, higher NHR emerged as a predictor of adverse clinical endpoints in COVID-19 patients with diabetes.28 Clinical investigations also revealed that NHR levels are markedly elevated in metabolic syndrome (MetS) patients, and show strong associations with key cardio-metabolic parameters and insulin resistance.14,29 Consistent with previous studies, our results demonstrate a significant association between NHR and diabetes incidence. Interestingly, studies have shown a U-shaped relationship between HDL-C and the risk of cardiovascular events.30 Unlike this, our research found that NHR did not show a U-shaped relationship with the risk of diabetes. Instead, the incidence of diabetes increased with the increase of NHR. What’s more, we found that adding NHR to FPG significantly enhanced diabetes risk discrimination and reclassification in healthy adults. Therefore, even the area under the ROC curve of NHR is smaller than under the ROC curve of HDL-c, NHR is a relatively more practical indicator in assisting in predicting the risk of diabetes. Evaluating this ratio may assist in identifying individuals at risk of transitioning to diabetes and facilitating the planning of lifestyle adjustments. However, in the natural history of diabetes development, whether NHR elevation precedes the onset of insulin resistance and β-cell dysfunction or whether it differentially relates to the development of diabetes dominated by insulin resistance or impaired insulin secretion, remains to be further investigated.

    The precise mechanisms linking elevated NHR to increased diabetes risk remain unclear, although it appears to be a relatively reliable indicator of MetS and insulin resistance. Experimental studies have shown that neutrophil count, as part of NHR, interact directly with CD11b and ICAM-1 on adipocytes,31 leading to an increased expression of IL-1β. The elevated secretion of IL-1β promotes macrophage infiltration, exacerbating inflammation in adipose tissue and ultimately contribute to the development of insulin resistance.32 Additionally, neutrophils can also impair insulin signaling through the nitrosylation of the β subunit of the insulin receptor and the degradation of insulin receptor substrate, as a result of the release of myeloperoxidase (MPO)33 and neutrophil elastase (NE).34 HDL-c, another component of NHR, was shown to modulate pancreatic beta-cell function and enhance insulin sensitivity through endoplasmic reticulum (ER) stress reduction and inhibiting apoptosis.35 Clinical trials have shown that HDL-c and apoA-I modulation, whether through acute rHDL infusion or chronic CETP inhibition, improves glycemic control in type 2 diabetes patients.36 Furthermore, Studies show HDL-c modulates neutrophil activity by suppressing proliferation and migration.37 However, the roles of neutrophils and HDL-c in the processes of insulin resistance and islet secretory dysfunction remain inadequately elucidated and require further investigation and confirmation, particularly in clinical studies.

    Metabolic inflammation tends to escalate with advancing age, and adoption of unhealthy lifestyles, including insufficient physical activity.38,39 Contrary to expectations, our study revealed no notable elevation in diabetes risk associated with a higher NHR among alcohol consumers. This finding is in line with the research by Llamosas-Falcón et al, which indicates that moderate alcohol consumption decreases diabetes risk, whereas excessive drinking elevates it.40 The protective effect of alcohol may offset the influence of NHR. Nevertheless, among individuals who are physically active or have good sleep quality, a higher NHR was associated with an increased risk of diabetes, whereas this was not observed in inactive or poorly sleeping individuals. Low physical activity and poor sleep quality, which are linked to elevated levels of C-reactive protein (CRP) and cytokines due to obesity or impaired inflammatory metabolism, exacerbate the risk of inflammatory diseases such as diabetes.41 Short sleep duration is also associated with inflammation, oxidative stress, as well as increased risks of type 2 diabetes mellitus (T2DM).42 This could potentially be attributed to the disruption of immune and inflammatory regulation resulting from inadequate exercise and poor sleep quality, which in turn diminishes the predictive effect of NHR. Research indicates that engaging in regular physical activity can prevent diabetes and enhance sleep quality. However, self-reported sleep quality assessments require corroboration through objective measurement tools for accuracy.

    Subgroup analysis by age indicated a stronger association of NHR with diabetes incidence in individuals with age (≥40 years old). Conversely, the relationship was weaker in those younger than 40 years of age. It is consistent with previous research emphasizing age as a critical risk factor for diabetes43 and its impact on both neutrophil44 and HDL-c45 levels. By subgroup analysis, we also found that the incidence of new-onset diabetes in the subgroup with anxiety or depression was higher than in the other subgroup, though psychological status was assessed using individuals completing health questionnaires, rather than standardized psychological assessment scales. Prior studies have suggested that anxiety and depression, prevalent mental disorders may contribute to diabetes through excessive HPA axis activity and insulin resistance.46

    This study has certain limitations. First, the absence of 2-hour post-OGTT blood glucose for diagnosing at baseline and follow-up in this study potentially compromised the accuracy of the results. At baseline, the deficiency of 2-hour post-OGTT blood glucose may lead to the accidental inclusion of patients with hyperglycemia after glucose loading as the normal blood glucose population in this study. During the follow-up process, diabetic patients diagnosed solely based on hyperglycemia after glucose loading may be missed. Subsequent studies will further investigate the relationship between NHR and the incidence of diabetes in the healthy physical examination population who regularly complete the OGTT examination. Second, China ranks as one of the nations with the lowest incidence rates of Type 1 Diabetes Mellitus (T1DM), exhibiting an incidence rate of roughly 1.01 cases per 100,000 people per year.47 As a result, the probability of encountering T1DM cases within the scope of this study is deemed minimal. Third, NHR was only obtained at the baseline examination, it was impossible to consider the impact of fluctuating changes or the cumulative exposure on the diabetes incidence during the follow-up period. The impact of cumulative NHR exposure or fluctuations on the occurrence of diabetes needs to be further studied. Lastly, not all the participants had an annual physical examination every year, which may introduce bias in determining the date of diabetes diagnosis and consequently affect the accuracy of the cumulative occurrence rate of diabetes. Nevertheless, our study has certain advantages compared to other studies. We adopted a conservative methodology to mitigate potential biases. We excluded participants using lipid-lowering, antihypertensive, antihypertensive drugs, or hormone therapies due to the established diabetogenic potential of agents like some statins, beta-blockers, hormone therapies, or thiazide diuretics.48,49 Angiotensin converting enzyme inhibitors or omega-3 fatty acids could affect the study results by intervening in glucose or lipid metabolism.50 Additionally, this study comprises a stable and substantial cohort sourced from our hospital’s routine health examination population. The median follow-up duration was 5.1 years, which was relatively long. Given that chronic diseases, including diabetes, necessitate a considerable period from exposure to clinical onset, a sufficiently extended follow-up period is crucial for conducting a favorable analysis of the association.

    Conclusions

    Our results strongly suggested that NHR serves as an independent predictor for diabetes development in normoglycemic Chinese individuals. Monitoring the NHR as a qualified predictor and risk stratification tool deserves more attention in clinical practice for the ones with normoglycemia.

    Acknowledgment

    We thank Qian Chen for her help in programming and statistical analyses as well as all participants for their contribution.

    Author Contributions

    All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

    Funding

    Our work was funded by the grants from the National Natural Science Foundation of China No. 82470446 to YaPei Li), Natural Science Foundation of Hunan Province (No. 2025JJ50526 to Zi Chen, No. 2022JJ20091 to YaPei Li).

    Disclosure

    The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

    References

    1. Genitsaridi I, Salpea P, Salim A, et al. Idf diabetes atlas: global, regional and national diabetes prevalence estimates for 2024 and projections for 2050.

    2. Ke C, Narayan KMV, Chan JCN, Jha P, Shah BR. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat Rev Endocrinol. 2022;18(7):413–432. doi:10.1038/s41574-022-00669-4

    3. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. doi:10.3390/ijms21176275

    4. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–476. doi:10.1038/nrd4275

    5. Eguchi K, Nagai R. Islet inflammation in type 2 diabetes and physiology. J Clin Invest. 2017;127(1):14–23. doi:10.1172/JCI88877

    6. Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015;2015:508409. doi:10.1155/2015/508409

    7. Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022;19(2):177–191. doi:10.1038/s41423-021-00832-3

    8. Lee CT, Harris SB, Retnakaran R, et al. White blood cell subtypes, insulin resistance and β-cell dysfunction in high-risk individuals–the PROMISE cohort. Clin Endocrinol. 2014;81(4):536–541. doi:10.1111/cen.12390

    9. McGrath KC, Li XH, Whitworth PT, et al. High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation. J Lipid Res. 2014;55(3):421–430. doi:10.1194/jlr.M043281

    10. Fiorentino TV, Succurro E, Marini MA, et al. HDL cholesterol is an independent predictor of β-cell function decline and incident type 2 diabetes: a longitudinal study. Diabetes Metab Res Rev. 2020;36(4):e3289. doi:10.1002/dmrr.3289

    11. Cao C, Hu H, Zheng X, Zhang X, Wang Y, He Y. Non-linear relationship between high-density lipoprotein cholesterol and incident diabetes mellitus: a secondary retrospective analysis based on a Japanese cohort study. BMC Endocr Disord. 2022;22(1):163. doi:10.1186/s12902-022-01074-8

    12. Khedr D, Hafez M, Lumpuy-Castillo J, et al. Lipid biomarkers as predictors of diastolic dysfunction in diabetes with poor glycemic control. Int J Mol Sci. 2020;21(14):5079. doi:10.3390/ijms21145079

    13. Xepapadaki E, Nikdima I, Sagiadinou EC, Zvintzou E, Kypreos KE. HDL and type 2 diabetes: the chicken or the egg? Diabetologia. 2021;64(9):1917–1926. doi:10.1007/s00125-021-05509-0

    14. Jialal I, Jialal G, Adams-Huet B, Ramakrishnan N. Neutrophil and monocyte ratios to high-density lipoprotein-cholesterol and adiponectin as biomarkers of nascent metabolic syndrome. Hormone Mol Biol Clin Invest. 2020;41(2). doi:10.1515/hmbci-2019-0070

    15. Huang JB, Chen YS, Ji HY, et al. Neutrophil to high-density lipoprotein ratio has a superior prognostic value in elderly patients with acute myocardial infarction: a comparison study. Lipids Health Dis. 2020;19(1):59. doi:10.1186/s12944-020-01238-2

    16. Başyiğit F, Çöteli C. Relationship between the neutrophil to HDL-C ratio and anatomical significance of coronary artery stenosis in patients with documented myocardial ischemia. Eur Rev Med Pharmacol Sci. 2022;26(9):3179–3184. doi:10.26355/eurrev_202205_28735

    17. ElSayed NA, Aleppo G, Bannuru RR. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20–s42. doi:10.2337/dc24-S002

    18. Hosseini Mojahed F, Aalami AH, Pouresmaeil V, Amirabadi A, Qasemi Rad M, Sahebkar A. Clinical evaluation of the diagnostic role of MicroRNA-155 in breast cancer. Int J Genomics. 2020;2020:9514831. doi:10.1155/2020/9514831

    19. Santulli G, Pascale V, Finelli R, et al. We are what we eat: impact of food from short supply chain on metabolic syndrome. J Clin Med. 2019;8(12):2061. doi:10.3390/jcm8122061

    20. Yan G, Li F, Elia C, et al. Association of lipid accumulation product trajectories with 5-year incidence of type 2 diabetes in Chinese adults: a cohort study. Nutr Metab. 2019;16(1):72. doi:10.1186/s12986-019-0399-7

    21. Man REK, Charumathi S, Gan ATL, et al. Cumulative incidence and risk factors of prediabetes and type 2 diabetes in a Singaporean Malay cohort. Diabetes Res Clin Pract. 2017;127:163–171. doi:10.1016/j.diabres.2017.03.007

    22. Wrona M, Skrypnik D. New-onset diabetes mellitus, hypertension, dyslipidaemia as sequelae of COVID-19 infection-systematic review. Int J Environ Res Public Health. 2022;19(20):13280. doi:10.3390/ijerph192013280

    23. Metwally AA, Mehta P, Johnson BS, Nagarjuna A, Snyder MP. COVID-19-induced new-onset diabetes: trends and technologies. Diabetes. 2021;70(12):2733–2744. doi:10.2337/dbi21-0029

    24. Ilic I, Ilic M. Diabetes mellitus after SARS-CoV-2 infection: an epidemiological review. Life. 2023;13(6):1233. doi:10.3390/life13061233

    25. Liu J, Chen K, Tang M, et al. Oxidative stress and inflammation mediate the adverse effects of cadmium exposure on all-cause and cause-specific mortality in patients with diabetes and prediabetes. Cardiovasc Diabetol. 2025;24(1):145. doi:10.1186/s12933-025-02698-5

    26. Song Y, Zhao Y, Shu Y, et al. Combination model of neutrophil to high-density lipoprotein ratio and system inflammation response index is more valuable for predicting peripheral arterial disease in type 2 diabetic patients: a cross-sectional study. Front Endocrinol. 2023;14:1100453. doi:10.3389/fendo.2023.1100453

    27. Ren H, Zhu B, Zhao Z, et al. Neutrophil to high-density lipoprotein cholesterol ratio as the risk mark in patients with type 2 diabetes combined with acute coronary syndrome: a cross-sectional study. Sci Rep. 2023;13(1):7836. doi:10.1038/s41598-023-35050-6

    28. Wang Y, Zhang J, Li H, et al. Prognostic value of leucocyte to high-density lipoprotein-cholesterol ratios in COVID-19 patients and the diabetes subgroup. Front Endocrinol. 2021;12:727419. doi:10.3389/fendo.2021.727419

    29. Chen T, Chen H, Xiao H, et al. Comparison of the value of neutrophil to high-density lipoprotein cholesterol ratio and lymphocyte to high-density lipoprotein cholesterol ratio for predicting metabolic syndrome among a population in the Southern Coast of China. Diabetes, Metabolic Syndrome Obesity. 2020;13:597–605. doi:10.2147/DMSO.S238990

    30. Trimarco V, Izzo R, Morisco C, et al. High HDL (High-Density Lipoprotein) cholesterol increases cardiovascular risk in hypertensive patients. Hypertension. 2022;79(10):2355–2363. doi:10.1161/HYPERTENSIONAHA.122.19912

    31. Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res. 2008;49(9):1894–1903. doi:10.1194/jlr.M800132-JLR200

    32. Watanabe Y, Nagai Y, Honda H, et al. Bidirectional crosstalk between neutrophils and adipocytes promotes adipose tissue inflammation. FASEB J. 2019;33(11):11821–11835. doi:10.1096/fj.201900477RR

    33. Nessler K, Grzybczak R, Nessler M, Zalewski J, Gajos G, Windak A. Associations between myeloperoxidase and paraoxonase-1 and type 2 diabetes in patients with ischemic heart disease. BMC Cardiovasc Disord. 2022;22(1):521. doi:10.1186/s12872-022-02928-8

    34. Talukdar S, Oh DY, Bandyopadhyay G, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nature Med. 2012;18(9):1407–1412. doi:10.1038/nm.2885

    35. Chapman MJ. HDL functionality in type 1 and type 2 diabetes: new insights. Curr Opinionendocrinol Diabetes Obesity. 2022;29(2):112–123. doi:10.1097/MED.0000000000000705

    36. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119(15):2103–2111. doi:10.1161/CIRCULATIONAHA.108.843219

    37. Curcic S, Holzer M, Frei R, et al. Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL. BBA. 2015;1851(2):184–193. doi:10.1016/j.bbalip.2014.11.010

    38. Lankila H, Kekäläinen T, Hietavala EM, Laakkonen EK. A mediating role of visceral adipose tissue on the association of health behaviours and metabolic inflammation in menopause: a population-based cross-sectional study. Sci Rep. 2025;15(1):1999. doi:10.1038/s41598-025-85134-8

    39. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576–590. doi:10.1038/s41574-018-0059-4

    40. Llamosas-Falcón L, Rehm J, Bright S, et al. The relationship between alcohol consumption, BMI, and type 2 diabetes: a systematic review and dose-response meta-analysis. Diabetes Care. 2023;46(11):2076–2083. doi:10.2337/dc23-1015

    41. Piotrowska K, Zgutka K, Tkacz M, Tarnowski M. Physical activity as a modern intervention in the fight against obesity-related inflammation in type 2 diabetes mellitus and gestational diabetes. Antioxidants. 2023;12(8):1488. doi:10.3390/antiox12081488

    42. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab. 2004;89(5):2119–2126. doi:10.1210/jc.2003-031562

    43. O’Brien MJ, Zhang Y, Bailey SC, et al. Screening for prediabetes and diabetes: clinical performance and implications for health equity. Am J Preventive Med. 2023;64(6):814–823. doi:10.1016/j.amepre.2023.01.007

    44. Wenisch C, Patruta S, Daxböck F, Krause R, Hörl W. Effect of age on human neutrophil function. J Leukocyte Biol. 2000;67(1):40–45. doi:10.1002/jlb.67.1.40

    45. Berrougui H, Isabelle M, Cloutier M, Grenier G, Khalil A. Age-related impairment of HDL-mediated cholesterol efflux. J Lipid Res. 2007;48(2):328–336. doi:10.1194/jlr.M600167-JLR200

    46. Habib S, Sangaraju SL, Yepez D, Grandes XA, Talanki Manjunatha R. The nexus between diabetes and depression: a narrative review. Cureus. 2022;14(6):e25611. doi:10.7759/cureus.25611

    47. Weng J, Zhou Z, Guo L, et al. Incidence of type 1 diabetes in China, 2010-13: population based study. BMJ. 2018;360(j5295). doi:10.1136/bmj.j5295

    48. Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med. 2021;181(12):1562–1574. doi:10.1001/jamainternmed.2021.5714

    49. Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398(10313):1803–1810. doi:10.1016/S0140-6736(21)01920-6

    50. Jaca A, Durão S, Harbron J. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. South Afr Med J. 2020;110(12):1158–1159. doi:10.7196/SAMJ.2020.v110i12.14730

    Continue Reading

  • Wins and WTCS return illume Ridenour’s stellar year

    Wins and WTCS return illume Ridenour’s stellar year

    It was a good time to catch Desirae Ridenour. Few athletes have this season.

    Amid a breathless year within which she has medalled on three continents, she was fresh off the back of consecutive Americas Cup victories in Canada. First in Montreal, then in Kelowna, she displayed the kind of stranglehold over the field that often is the hallmark of an athlete reaching new levels. Prior to that, Ridenour had medalled in the French Grand Prix and at the Holten Europe Cup, made a return to the WTCS after a seven-year absence, and won the Napier World Cup. The moment was therefore ripe to look back over a whirlwind six months with an athlete that appears close to gatecrashing the big-time.

    “Napier was definitely a high point for me,” said Ridenour. “That was the first race of the season and I’ve never won a World Cup before, and I did not expect it to happen so quickly. So I think that was probably the best race for me this season (so far), plus it also gave me the confidence for the other races later on.”

    “I did a stint in Europe recently and I came 2nd in Holten and 3rd at a French Grand Prix race, which was pretty stacked; I was behind Jeanne Lehair and Leonie Periault. That was really cool. But Napier just got the ball rolling, and I think that’s how I was able to do so well in some of these other races later on in the season.”

    Changes have been afoot for the Canadian star lately. In the last two years she has switched coach, environment, partner and more. Nowadays she is based in New Zealand for large swathes of the year, a shift that involved moving to the other side of the world. “I think the change has helped immensely in this success that I’ve been seeing so far.”

    “In the past couple of years, I was just constantly injured and I was never able to train properly or race properly.” Now however, “I’m going into the race with so much more confidence and in a way, it’s more fun for me. So there’s actually less pressure and – obviously I want to do well – if it doesn’t happen, I don’t think I’m going to take it personally. I’ll just be like, ‘oh, it’s just an off day’ and I can just move on.”

    “That mentality is something new that I think I’ve been able to learn this year, which is nice because you can’t always have a good day every day. I’ve learned that I’ve raced better when I just have fun, and even when I go to training, as long as I try my best and have fun, then I think everything’s going to work out.”

    It was also a good time to talk to Ridenour with an eye ahead on her second act for 2025. WTCS French Riviera is coming up at the end of August, a race that will stand as her third Series appearance ever having made a long-awaited comeback last month.

    Ridenour made her WTCS debut in 2018 when she was still a junior athlete. She had attained multiple promising results at the time, including a victory at the Asia Cup level. Conversely, with the benefit of hindsight, her debut may have come a touch too soon.

    “I think during that time, there was a lot of pressure. The coach I had at the time, I think they saw a lot of potential in me, and I think they kind of pushed me into a lot of higher level racing. So I think I skipped quite a few levels. I just felt a lot of pressure to perform, even though I was a junior and no one expected anything of me.”

    Indeed, there was a risk that 2018 would prove a false dawn. Injuries plagued Ridenour’s subsequent seasons, particularly from 2020 to 2023, hampering her progress. “I was really struggling in the sport,” she openly admitted. “I think there were times I was like, ‘I don’t know if I want to do this anymore’.”

    However, Ridenour did not throw in the towel and she made it back to the WTCS at the previous round in Hamburg. Relief was the feeling she felt the most given she did not know if she was going to make the start line until the day before.

    “Mentally, it was hard to come around it and I think Hamburg was the fourth race I had done in five weeks. So I was pretty exhausted.”

    “It’s funny, because I got like 50m into the swim and I just felt like something was off. Like, it wasn’t my normal self. And so I think I knew it was going to be a really hard day. When I came out of the swim, I felt like I was so far behind, which is not usually what happens.” (Note, Ridenour exited the water ahead of WTCS medallists and renowned swimmers Olivia Mathias, Georgia Taylor-Brown and Emma Lombardi.) “Usually I can fight through if I’m feeling slightly off, but I just couldn’t on the day. So I know that even if I didn’t have my best performance and it was a bad day (she placed 32nd, the only international finish in which she has not medalled since June 2024), I was still able to do at least something.”

    Ridenour Hamburg 2025

    At this point in her career, Ridenour’s most obvious strengths lie in the swim and bike, both of which have proven instrumental to her visits to various podiums this season. As such, when Hamburg turned into a running race, with a front pack of around fifty women, a dream return to the Series was beyond reach.

    “It was quite sketchy (with so many athletes in the pack) and it was quite hard to move up. Then it’s obviously kind of hard running with fifty other girls. And when some of them are running 15:30… Yeah.”

    Her running is something that she is building, notwithstanding that she acknowledged she currently runs less than a lot of her rivals in training. Her more immediate focus, though, is her next stab at the WTCS.

    “There’s always a bit of nervousness, especially as I haven’t had the biggest training block because of all the races, even though racing does give you a huge stimulus and it’s obviously really good practice. But I have been training consistently for the last little while and I think you can’t really forget about all the training you have behind you. You just need to take that into the race and whatever happens, happens. I’m going in there with an open mind and trying to not be as nervous as I was in Hamburg and to have a bit more fun with it.”

    In France they say the first crepe is for the dog. Perhaps a similar insouciance is required when considering Ridenour’s Hamburg outing, as is a quiet confidence that WTCS French Riviera could be her chance to shine. After all, there will be a sea swim – a style in which she had often thrived this year – as well as a bike course that could suit her very nicely.

    If she were to stop right now, Ridenour’s 2025 could only be described as a resounding success. Yet with more WTCS appearances to come, her fantastic year could be about to get even better.

    Continue Reading

  • NASA-funded Compact Radar Drives Big Changes in Airborne and Suborbital Radar Capabilities

    NASA-funded Compact Radar Drives Big Changes in Airborne and Suborbital Radar Capabilities

    A collaboration between NASA and the small business Aloft Sensing produced a new compact radar system that will enable researchers to leverage High Altitude Long Endurance (HALE) platforms to observe dynamic Earth systems. This new radar is small, provides highly sensitive measurements, and doesn’t require GPS for positioning; eventually, it could be used on vehicles in space.

    Long before a volcano erupts or a mountainous snowpack disappears, millimeter-scale changes in Earth’s surface indicate larger geologic processes are at work. But detecting those minute changes, which can serve as early warnings for impending disasters, is difficult.

    With support from NASA’s Earth Science Technology Office (ESTO ) a team of researchers from the small aerospace company Aloft Sensing is developing a compact radar instrument for observing Earth’s surface deformation, topography, and vegetation with unprecedented precision.

    Their project, “HALE InSAR,” has demonstrated the feasibility of using high-altitude, long-endurance (HALE) vehicles equipped with Interferometric Synthetic Aperture Radar (InSAR) to observe changes in surface deformation mere millimeters in size and terrain information with centimetric vertical accuracy.

    “It’s a level of sensitivity that has eluded traditional radar sensors, without making them bulky and expensive,” said Lauren Wye, CEO of Aloft Sensing and principal investigator for HALE InSAR.

    HALE vehicles are lightweight aircraft designed to stay airborne for extended periods of time, from weeks to months and even years. These vehicles can revisit a scene multiple times an hour, making them ideal for locating subtle changes in an area’s geologic environment.

    InSAR, a remote sensing technique that compares multiple images of the same scene to detect changes in surface topography or determine structure, is also uniquely well-suited to locate these clues. But traditional InSAR instruments are typically too large to fly aboard HALE vehicles.

    HALE InSAR is different. The instrument is compact enough for a variety of HALE vehicles, weighing less than 15 pounds (seven kilograms) and consuming fewer than 300 watts of power, about as much energy as it takes to power an electric bike.

    HALE InSAR leverages previously-funded NASA technologies to make such detailed measurements from a small platform: a novel electronically steered antenna and advanced positioning algorithms embedded within an agile software-defined transceiver. These technologies were developed under ESTO’s Instrument Incubation Program (IIP) and Decadal Survey Incubation (DSI) Program, respectively.

    “All of the design features that we’ve built into the instrument are starting to showcase themselves and highlight why this payload in particular is distinct from what other small radars might be looking to achieve,” said Wye.

    One of those features is a flat phased array antenna, which gives users the ability to focus HALE InSAR’s radar beam without physically moving the instrument. Using a panel about the size of a tablet computer, operators can steer the beam electronically, eliminating the need for gimbles and other heavy components, which helps enable the instrument’s reduced size and weight.

    “SAR needs to look to the side. Our instrument can be mounted straight down, but look left and right on every other pulse such that we’re collecting a left-looking SAR image and a right-looking SAR image essentially simultaneously. It opens up opportunities for the most mass-constrained types of stratospheric vehicles,” said Wye.

    Using advanced positioning algorithms, HALE InSAR also has the unique ability to locate itself without GPS, relying instead on feedback from its own radar signals to determine its position even more accurately. Brian Pollard, Chief Engineer at Aloft Sensing and co-investigator for HALE InSAR, explained that precise positioning is essential for creating high-resolution data about surface deformation and topography.

    “SAR is like a long exposure camera, except with radio waves. Your exposure time could be a minute or two long, so you can imagine how much smearing goes on if you don’t know exactly where the radar is,” said Pollard.

    Navigating without GPS also makes HALE InSAR ideal for field missions in austere environments where reliable GPS signals may be unavailable, increasing the instrument’s utility for national security applications and science missions in remote locations.

    The Aloft Sensing team recently achieved several key milestones, validating their instrument aboard an airship at 65,000 feet as well as small stratospheric balloons. Next, they’ll test HALE InSAR aboard a fixed wing HALE aircraft. A future version of their instrument could even find its way into low Earth orbit on a small satellite.

    Wye credits NASA support for helping her company turn a prototype into a proven instrument.

    “This technology has been critically enabled by ESTO, and the benefit to science and civil applications is huge,” said Wye. “It also exemplifies the dual-use potential enabled by NASA-funded research. We are seeing significant military interest in this capability now that it is reaching maturity. As a small business, we need this hand-in-hand approach to be able to succeed.”

    For more information about opportunities to work with NASA to develop new Earth observation technologies, visit esto.nasa.gov.

    For additional details, see the entry for this project on NASA TechPort.

    Project Lead: Dr. Lauren Wye, CEO, Aloft Sensing

    Sponsoring Organization: NASA’s Instrument Incubation Program (IIP)

    Continue Reading

  • Palihapitiya returns to SPAC market with American Exceptionalism’s IPO filing

    Palihapitiya returns to SPAC market with American Exceptionalism’s IPO filing

    (Reuters) -Venture investor Chamath Palihapitiya, dubbed Wall Street’s “SPAC king” for his high-profile blank-check deals, is set to take his latest special purpose acquisition vehicle public, marking his return to the market after several years.

    American Exceptionalism Acquisition Corp, chaired by Palihapitiya, will list on the New York Stock Exchange under the ticker ‘AEXA’, a filing showed late on Monday. The SPAC plans to raise $250 million to target companies in artificial intelligence, energy, decentralized finance and defense sectors.

    A SPAC is a shell firm that raises money through an IPO to merge with a private business and take it public, offering companies an alternative route to the market that bypasses the longer and more costly traditional IPO process.

    SPAC deals hit record levels in 2020 and 2021, before activity slowed sharply in the following years as regulatory scrutiny increased and investors soured on the once-popular vehicle.

    During the peak, several Wall Street heavyweights, including billionaire investors Bill Ackman and Michael Klein, joined Palihapitiya in betting on SPACs as the next big trend in the listings market.

    Despite backing from big-name investors, many SPACs failed to secure merger targets, while others completed deals with heavy redemptions or saw their shares plunge after debut.

    But Palihapitiya strongly believes in the vehicle. “When I raised my first SPAC in 2017, I wanted to help correct an increasingly unstable balance between the private and public markets,” he said in a letter to investors.

    “While SPACs are not the solution for every issue in the IPO process, I continue to believe that they have an important piece to play in capital formation – and especially now.”

    SoFi Technologies is among Palihapitiya’s most successful bets, with the consumer lender now valued at nearly $29 billion. In January 2021, it had agreed to go public in a blank-check deal valued at around $8.65 billion.

    (Reporting by Manya Saini in Bengaluru; Editing by Shinjini Ganguli)

    Continue Reading

  • Air Canada flight attendants reach ‘tentative’ deal with airline to end strike | Canada

    Air Canada flight attendants reach ‘tentative’ deal with airline to end strike | Canada

    Air Canada flight attendants say they have reached a “tentative” deal with the airline to end a strike over wages and ground work that has cancelled travel for half a million people worldwide.

    Roughly 10,000 flight attendants walked off the job after midnight Saturday, insisting Air Canada had failed to address their demands for higher pay and compensation for unpaid ground work, including during boarding.

    The attendants’ union defied two orders from a regulatory tribunal to return to work, forcing Air Canada to roll back plans to partially restore service.

    But after resuming talks on Monday evening, the union said it had reached a potential deal with the airline that it would put to its members for consideration.

    “The strike has ended. We have a tentative agreement we will bring forward to you,” the Canadian Union of Public Employees’ (Cupe) Air Canada branch said in a statement.

    “We are required to advise our membership that we must fully cooperate with resumption of operations,” the statement said.

    Air Canada said in a statement that it would “gradually restart its operations” after reaching an agreement with Cupe through a mediator, William Kaplan.

    It said the first flights were scheduled for Tuesday evening but warned that full service may not return for seven to 10 days.

    “Restarting a major carrier like Air Canada is a complex undertaking. Full restoration may require a week or more,” Air Canada president Michael Rousseau said.

    Neither the union nor the airline immediately provided details of the proposed agreement.

    But Cupe said the deal achieves “transformational change for our industry after a historic fight”.

    “Unpaid work is over,” it added, a reference to a key demand throughout the talks that flight attendants also be compensated for time not spent in the air.

    “When our rights were taken away, we stood strong, we fought back – and we secured a tentative agreement that our members can vote on,” Cupe further said.

    Air Canada said it would not comment on the terms of the deal “until the ratification process is complete”.

    It was not immediately clear when Cupe would schedule a vote.

    More travel disruption

    Air Canada – the national carrier which flies directly to 180 cities domestically and abroad – has said the strike forced cancellations impacting 500,000 people.

    Over the weekend, federal labor minister Patty Hajdu invoked a legal provision to halt the strike and force both sides into binding arbitration.

    Following that intervention, the Canada Industrial Relations Board (CIRB), a regulatory tribunal, ordered the flight attendants back to work in two separate orders – on Sunday and Monday.

    But the union said it would not comply with the orders, forcing Air Canada to walk back service resumption plans.

    Air Canada told customers on Tuesday to expect continued disruption “as aircraft and crew are out of position”.

    It urged passengers to only travel to the airport if their flight was shown as operating.

    “The suspension of our service is extremely difficult for our customers. We deeply regret and apologize for the impact on them of this labour disruption,” Rousseau said.

    Prime minister Mark Carney told reporters Monday it was “disappointing” that eight months of negotiations between the carrier and union had not produced an agreement.

    He said it was “important” that flight attendants were “compensated equitably”, but voiced unease that hundreds of thousands of people were facing travel uncertainty.

    Continue Reading

  • David Arquette says ‘Scream’ cast and Courteney Cox were worried sick about him

    David Arquette says ‘Scream’ cast and Courteney Cox were worried sick about him

    David Arquette recalls ‘Scream’ cast worrying he would ‘hurt himself’

    David Arquette once left his then-girlfriend, Courteney Cox and the rest of the Scream 2 cast afraid that he’d hurt himself.

    While filming the Scream sequel, the actor’s mother was sick and dying, and he was struggling with work and grief. David detailed the experience in Ashley Cullins‘ tell-all book, Your Favorite Scary Movie: How the Scream Films Rewrote the Rules of Horror.

    “Scream 2 was really hard for me,” Arquette shared. “My mom was really sick and about to die.”

    He revealed that the director talked to him about his struggles and shared some words of wisdom.

    He continued, “When we had gotten back to L.A., [director Wes Craven] just sat me down and gave me this really sweet man-to-man, fatherly conversation that had a huge impact on my life.”

    He added, “It was just about ‘I know you’re going through a hard time, but I really want to see you do great things and get your life together.’”

    “At the time, I was dating Courteney, we were on-and-off. And he said, ‘I think she really likes you, but she’s scared like a lot of people are that you’re gonna hurt yourself,’” Arquette continued recalling what the director said. “It was something that not a lot of people do in Hollywood.”

    David met the Friends star while filming the first Scream film in 1996 and they tied the knot in 1999. The couple welcomed daughter Coco and got divorced in 2013.

    David Arquette is now married to Christina McLarty, with whom he shares kids Charlie, 8, and Augustus, 5. He’s returning as Deputy Dewey in Scream 7 alongside Courteney Cox.


    Continue Reading